PIM1 and Familial prostate cancer: Early efforts focused on PIM1 specifically, and a compound with potent PIM1 inhibitory activity, SGI-1776 [28], entered phase 1 clinical evaluation for patients with relapsed or refractory prostate cancer or lymphoma in 2008.